ALDX

Aldeyra Therapeutics, Inc. (ALDX) | Rumor.io

Aldeyra Therapeutics

ALDX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,721

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.09

Market capitalization70M

Earnings per share-0.38

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-33.8M

Social

What share of all stock conversation is about ALDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 29

Aldeyra Therapeutics ($ALDX) is appealing the FDA's third rejection of its dry eye disease candidate reproxalap, with a Formal Dispute Resolution Request.
The company has three NDA submissions and three Complete Response Letters (CRLs) from the FDA, with the most recent CRL citing "inconsistency" in the totality of evidence.
Despite the setbacks, Aldeyra Therapeutics' shares are trading higher, with a +11.54% gain today, and a target price of $9.00 from BTIG with a Buy rating.

Generated by AI

Sentiment

Of the messages about ALDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	61.68% -22.39
Bearish	0%	0%	0% 0	38.32% +22.39

Bullish· Mar 23

$ALDX has shown a significant surge in price, breaching the $1.98 resistance and reaching a high of $2.30, with a 26.80% increase.
The stock's momentum has been driven by a confirmed product-market fit, with a strategic alliance being a key catalyst for the reversal.
$ALDX has a high-conviction technical reversal in play, with a target price of $2.85, following a 67% sell-off earlier in the week.

Bearish· Mar 18

Aldeyra Therapeutics, Inc. (ALDX) has seen a significant decline of ~70% after the FDA rejection of its dry eye disease treatment, reproxalap, citing insufficient efficacy data.
HC Wainwright downgraded ALDX from Buy to Neutral, lowering the price target from $10 to $2, following the FDA setback.
The company's CEO, Todd Zaun, has been criticized for his handling of the situation, with some calling for his removal due to concerns over his leadership and potential fraudulent activities.

Generated by AI

Topics

Of the messages about ALDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	77.14%
Controversies	0%	0%	0%	5.71%
Technical Analysis	0%	0%	0%	8.69%
Analysts	0%	0%	0%	6.4%
Earnings	0%	0%	0%	0.23%
Macro	0%	0%	0%	1.83%

Earnings· Nov 9

Aldeyra Therapeutics, Inc. (ALDX) reported a narrower-than-expected loss per share, beating estimates by $0.07.
This earnings beat may be a positive catalyst for the stock.
The company's ability to outperform expectations could indicate a potential turnaround in its financial performance.

Analysts· Dec 21

Analysts have lowered price targets for Aldeyra Therapeutics (ALDX) with Citigroup and SVB Leerink reducing targets to $21 and $15, respectively.
Analysts remain confident in ALDX, with a buy consensus of 88% among 16 analysts.
Recent clinical trial updates for ALDX have been well-tolerated, with no safety signals observed, and top-line results are expected in mid-2022.

Announcements· Mar 17

The FDA has rejected Aldeyra Therapeutics' experimental dry eye disease treatment, reproxalap, for the third time, citing lack of evidence and inconsistency of study results.
The company does not expect to pursue additional trials for reproxalap, and its shares have plummeted 74% in premarket trading.
Aldeyra Therapeutics has a cash reserve of $70 million, which is expected to support operations until 2028, and the company has several other drugs in its pipeline.

Technical Analysis· Mar 23

$ALDX decisively breached the $1.98 resistance on 3.57M volume, signaling powerful momentum ignition and a 23.48% surge to $2.24.
The technical target aligns at $2.93 following the recent capitulation, with institutional conviction confirmed by the volume surge to 3.62M.
The asset's technical reversal is now in motion, with a target of $2.96 following a 67% washout that reset the base.

Generated by AI

Community

Of the messages about ALDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	45.45%	42.86%	22.68%	62.62%
Newcomers	54.55%	57.14%	77.32%	37.38%

Regulars· Mar 17

The FDA has extended the PDUFA date for Reproxalap, and the reason for this extension is unclear, leading to speculation and concern among regular investors.
The FDA has requested additional field trial data for Reproxalap, which the company had previously been told was not necessary, and this reversal is seen as a setback for Aldeyra Therapeutics.
The FDA has issued a Complete Response Letter (CRL) for Reproxalap, stating that it does not recommend conducting additional trials, and the company intends to request a Type A meeting to discuss the decision.

Newcomers· Sep 29

Newcomers are focused on Aldeyra Therapeutics' ($ALDX) plan to appeal the FDA's rejection of its dry eye disease treatment, reproxalap, through a Formal Dispute Resolution Request.
The company has a history of three NDA submissions, three CRLs (FDA rejections), and zero approvals, with the FDA citing "inconsistency" in the totality of evidence.
Aldeyra Therapeutics has $45.1M in cash and is focused on progressing its clinical trial results, with the company intending to submit a Formal Dispute Resolution Request to the FDA.

Generated by AI

News

Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL

Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.

16h agoBenzinga

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c

20h agoYahoo Finance

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

20h agoYahoo Finance

Aldeyra to appeal FDA rejection of dry eye drug reproxalap

23h agoInvesting.com

Aldeyra Therapeutics to Host Regulatory Update Webcast

CONCORD, Mass., September 28, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

1d agoYahoo Finance Australia

Aldeyra Therapeutics Leases New Concord Headquarters Space

Detailed price information for Aldeyra Therapeu (ALDX-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about ALDX also mention

#	Name	Attention
1	Grace Therapeutics, Inc.GRCE	0%new
2	Fennec Pharmaceuticals Inc.FENC	0%0
3	Replimune Group, Inc.REPL	0%0
4	OKYO Pharma Ltd.OKYO	0%0
5	Regenxbio Inc.RGNX	0%+0
6	ALX Oncology Holdings Inc.ALXO	0%0
7	Travere Therapeutics Inc.TVTX	0%0
8	Milestone Pharmaceuticals Inc.MIST	0%+0
9	Silence Therapeutics Plc ADRSLN	0.01%new
10	Verrica Pharmaceuticals Inc.VRCA	0%0

Aldeyra Therapeutics, Inc.

Healthcare
Biotechnology

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its current pipeline centers on small-molecule and related drug candidates for ophthalmology and other inflammatory conditions, including reproxalap for dry eye disease and allergic conjunctivitis, ADX-2191 for selected retinal disorders, and ADX-629 for several immune-related indications. The company also advances preclinical reactive aldehyde species modulator programs aimed at addressing systemic and retinal diseases. Aldeyra Therapeutics emphasizes treatments designed to modulate inflammatory pathways and improve patient care across eye disease, allergy, and broader immune-mediated segments. Based in Lexington, Massachusetts, Aldeyra Therapeutics operates as a clinical-stage biopharmaceutical developer with a portfolio positioned across multiple therapeutic areas and specialty markets.

Website

Location

131 Hartwell Avenue

Lexington, MA, 02421

United States

Social

What share of all stock conversation is about ALDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 29

Aldeyra Therapeutics ($ALDX) is appealing the FDA's third rejection of its dry eye disease candidate reproxalap, with a Formal Dispute Resolution Request.
The company has three NDA submissions and three Complete Response Letters (CRLs) from the FDA, with the most recent CRL citing "inconsistency" in the totality of evidence.
Despite the setbacks, Aldeyra Therapeutics' shares are trading higher, with a +11.54% gain today, and a target price of $9.00 from BTIG with a Buy rating.

Generated by AI

Sentiment

Of the messages about ALDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	61.68% -22.39
Bearish	0%	0%	0% 0	38.32% +22.39

Bullish· Mar 23

$ALDX has shown a significant surge in price, breaching the $1.98 resistance and reaching a high of $2.30, with a 26.80% increase.
The stock's momentum has been driven by a confirmed product-market fit, with a strategic alliance being a key catalyst for the reversal.
$ALDX has a high-conviction technical reversal in play, with a target price of $2.85, following a 67% sell-off earlier in the week.

Bearish· Mar 18

Aldeyra Therapeutics, Inc. (ALDX) has seen a significant decline of ~70% after the FDA rejection of its dry eye disease treatment, reproxalap, citing insufficient efficacy data.
HC Wainwright downgraded ALDX from Buy to Neutral, lowering the price target from $10 to $2, following the FDA setback.
The company's CEO, Todd Zaun, has been criticized for his handling of the situation, with some calling for his removal due to concerns over his leadership and potential fraudulent activities.

Generated by AI

Topics

Of the messages about ALDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	77.14%
Controversies	0%	0%	0%	5.71%
Technical Analysis	0%	0%	0%	8.69%
Analysts	0%	0%	0%	6.4%
Earnings	0%	0%	0%	0.23%
Macro	0%	0%	0%	1.83%

Earnings· Nov 9

Aldeyra Therapeutics, Inc. (ALDX) reported a narrower-than-expected loss per share, beating estimates by $0.07.
This earnings beat may be a positive catalyst for the stock.
The company's ability to outperform expectations could indicate a potential turnaround in its financial performance.

Analysts· Dec 21

Analysts have lowered price targets for Aldeyra Therapeutics (ALDX) with Citigroup and SVB Leerink reducing targets to $21 and $15, respectively.
Analysts remain confident in ALDX, with a buy consensus of 88% among 16 analysts.
Recent clinical trial updates for ALDX have been well-tolerated, with no safety signals observed, and top-line results are expected in mid-2022.

Announcements· Mar 17

The FDA has rejected Aldeyra Therapeutics' experimental dry eye disease treatment, reproxalap, for the third time, citing lack of evidence and inconsistency of study results.
The company does not expect to pursue additional trials for reproxalap, and its shares have plummeted 74% in premarket trading.
Aldeyra Therapeutics has a cash reserve of $70 million, which is expected to support operations until 2028, and the company has several other drugs in its pipeline.

Technical Analysis· Mar 23

$ALDX decisively breached the $1.98 resistance on 3.57M volume, signaling powerful momentum ignition and a 23.48% surge to $2.24.
The technical target aligns at $2.93 following the recent capitulation, with institutional conviction confirmed by the volume surge to 3.62M.
The asset's technical reversal is now in motion, with a target of $2.96 following a 67% washout that reset the base.

Generated by AI

Community

Of the messages about ALDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	45.45%	42.86%	22.68%	62.62%
Newcomers	54.55%	57.14%	77.32%	37.38%

Regulars· Mar 17

The FDA has extended the PDUFA date for Reproxalap, and the reason for this extension is unclear, leading to speculation and concern among regular investors.
The FDA has requested additional field trial data for Reproxalap, which the company had previously been told was not necessary, and this reversal is seen as a setback for Aldeyra Therapeutics.
The FDA has issued a Complete Response Letter (CRL) for Reproxalap, stating that it does not recommend conducting additional trials, and the company intends to request a Type A meeting to discuss the decision.

Newcomers· Sep 29

Newcomers are focused on Aldeyra Therapeutics' ($ALDX) plan to appeal the FDA's rejection of its dry eye disease treatment, reproxalap, through a Formal Dispute Resolution Request.
The company has a history of three NDA submissions, three CRLs (FDA rejections), and zero approvals, with the FDA citing "inconsistency" in the totality of evidence.
Aldeyra Therapeutics has $45.1M in cash and is focused on progressing its clinical trial results, with the company intending to submit a Formal Dispute Resolution Request to the FDA.

Generated by AI

Aldeyra Therapeutics

Social

Sep 29

Bullish· Mar 23

Bearish· Mar 18

Earnings· Nov 9

Analysts· Dec 21

Announcements· Mar 17

Technical Analysis· Mar 23

Regulars· Mar 17

Newcomers· Sep 29

Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

Aldeyra to appeal FDA rejection of dry eye drug reproxalap

Aldeyra Therapeutics to Host Regulatory Update Webcast

Aldeyra Therapeutics Leases New Concord Headquarters Space

Also Discussed

Aldeyra Therapeutics, Inc.

Company Information

Location

Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

Aldeyra to appeal FDA rejection of dry eye drug reproxalap

Aldeyra Therapeutics to Host Regulatory Update Webcast

Aldeyra Therapeutics Leases New Concord Headquarters Space

Also Discussed

Social

Sep 29

Bullish· Mar 23

Bearish· Mar 18

Earnings· Nov 9

Analysts· Dec 21

Announcements· Mar 17

Technical Analysis· Mar 23

Regulars· Mar 17

Newcomers· Sep 29